Diaz Discusses the FDA Approval of Pembrolizumab for MSI-H Solid Tumors

Video

Luis A. Diaz Jr, MD, head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of pembrolizumab (Keytruda) for microsatellite instability-high (MSI-H) colorectal cancer and other tumor types.

Related Videos
Related Content